FMP
Charles River Laboratories International, Inc.
CRL
NYSE
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
171.04 USD
4.11 (2.4%)
2024
2023
2022
2021
4.05B
4.13B
3.98B
3.54B
2.72B
2.63B
2.51B
2.21B
1.33B
1.5B
1.46B
1.33B
1.1B
885.29M
811.68M
744.78M
0
0
0
0
751M
747.86M
665.1M
619.92M
0
0
0
0
0
0
0
0
353.47M
0
146.58M
124.86M
227.35M
617.26M
650.98M
589.86M
-134.23M
-35.98M
-27.99M
-109.15M
93.11M
581.28M
622.99M
480.71M
67.82M
100.91M
130.38M
81.87M
22.2M
474.62M
486.23M
390.98M
0.67
9.27
9.57
7.77
0.66
9.22
9.48
7.6
51.27M
51.23M
50.81M
50.29M
51.63M
51.45M
51.3M
51.42M
581.14M
1.03B
1.04B
854.29M
2024
2023
2022
2021
1.89B
1.43B
980.75M
625.41M
22.2M
474.62M
486.23M
390.98M
-119.17M
-24.16M
-38.65M
-40.71M
0
0
0
0
1.81B
1.89B
1.43B
980.75M
-194.29M
430.16M
413.5M
314.63M
2024
2023
2022
2021
2.02B
2.03B
1.86B
1.58B
361.74M
314.12M
303.87M
265.54M
-232.97M
-318.53M
-324.73M
-228.77M
1.89B
2.04B
1.88B
1.55B
2024
2023
2022
2021
-248.44M
245.14M
138.02M
902.71M
3.1B
2.85B
2.71B
1.81B
2.85B
3.1B
2.85B
2.71B
All figures are in USD.